Calls for papers
-
Inhaled drug developer Savara announced that it has entered into a definitive agreement for a private placement of common stock, pre-funded warrants, and milestone warrants with an expected $26.8 million in gross proceeds from sales… Read more . . .
-
CDMO MedPharm has announced the appointment of Lynn Allen as VP of Business Development, responsible for growing the business in North America. Allen has extensive experience in CDMO business development and was most recently Senior… Read more . . .
-
Finnish nanonization specialists Nanoform have filed for GMP certification with the Finnish Medicines Agency (FIMEA), the company said. In December 2018, Nanoform announced construction of a new GMP manufacturing facility in Helsinki. The company, which… Read more . . .
-
Australia’s Therapeutic Goods Administration has approved Ryaltris olopatadine hydrochloride/mometasone furoate nasal spray for the treatment of allergic rhinitis and rhinoconjunctivitis, Glenmark Pharmaceuticals said. The marketing application was submitted by Seqirus, which acquired Australian commercialization rights to… Read more . . .
-
For the second year in a row, the annual Drug Delivery to the Lungs meeting drew more than 850 OINDP specialists and 110 exhibitors to the Edinburgh International Conference Centre to catch up on the… Read more . . .
-
CDMO Recipharm has announced an investment of $450,000 for installation of a Proveris Scientific SprayView Measurement System at its facility in Research Triangle Park, North Carolina. The company described the SprayView system as “an important… Read more . . .
-
The European Commission has approved Janssen Pharmaceutical’s Spravato esketamine nasal spray for the treatment of treatment-resistant major depressive disorder, the company said. The EMA’s Committee for Medicinal Products for Human Use (CHMP) issued a positive… Read more . . .
-
Biohaven Pharmaceutical has announced that a Phase 2/3 trial of its intranasal vazegepant (BHV-3500) demonstrated that 10 and 20 mg doses of the intranasal migraine therapy were more effective than placebo for pain relief and… Read more . . .
-
3M has announced the sale of “substantially all” of 3M Drug Delivery Systems to Altaris Capital Partners for approximately $650 million. 3M will keep a 17% interest in the new business, which is expected to… Read more . . .
-
Spray characterization specialists Oxford Lasers have opened a new contract services facility to provide drug delivery device testing at their site in Didcot, UK, the company said. Oxford Lasers Imaging Division Manager Seamus Murphy said,… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
June 30: RespireX 2027, Boston, MA, USA